Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338211 | 0.87 | USP2 (0.50) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL13030026 | 0.83 | LMNA (0.46) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL3706344 | 0.81 | ALDH1A1 (0.55) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL7618433 | 0.81 | USP2 (0.55) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL10803892 | 0.80 | CA1 (0.57) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL1762507 | 0.80 | KDM4E (0.43) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL23149218 | 0.79 | USP2 (0.52) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL30469514 | 0.79 | USP2 (0.52) | USP2TSHRALDH1A1KDM4ELMNA | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.78 | USP2 (0.75) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL26211977 | 0.78 | GSTK1 (0.47) | USP2TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233638-A1 | RADIOPHARMACEUTICAL IMAGING METHOD OF ADENOMYOSIS | SERAC HEALTHCARE LTD (GB) | 2025-11-13 | — | — | WO | disclosed |
| US-20250186633-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | SERAC HEALTHCARE LTD (GB) | 2025-06-12 | — | — | US | disclosed |
| CN-118785926-A | Imaging integrin expression and intrauterine method for imaging a site of endometriosis | 赛瑞科医疗有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-11723991-B2 | Radiopharmaceutical compositions | SERAC HEALTHCARE LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20210060189-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | SERAC HEALTHCARE LIMITED (GB) | 2021-03-04 | — | — | US | disclosed |
| US-10758635-B2 | Radiopharmaceutical compositions | SERAC HEALTHCARE LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| EP-2598175-B1 | RADIOPHARMACEUTICAL COMPOSITIONS | SERAC HEALTHCARE LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-2680888-B1 | TECHNETIUM LABELLED PEPTIDES | GE HEALTHCARE LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9259496-B2 | Technetium labelled peptides | GE HEALTHCARE LIMITED (GB) | 2016-02-16 | — | — | US | disclosed |
| US-8852550-B2 | Chelator conjugates | GE HEALTHCARE LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20060120956-A1 | Imaging agents comprising barbituric acid derivatives | KOPKA KLAUS | 2006-06-08 | — | — | US | disclosed |
| WO-2006032911-A2 | METALLOPROTEINASE INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
| EP-1404377-B1 | IMPROVED CHELATOR CONJUGATES | GE HEALTHCARE LTD (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1549317-A1 | IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES | GE Healthcare Limited (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005053752-A2 | NOVEL IMAGING AGENTS COMPRISING CASPASE-3 INHIBITORS | GE HEALTHCARE LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005049005-A1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20040258619-A1 | Diaminedioxime radiometal complexes | GE HEALTHCARE LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| WO-2004032936-A1 | IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES | AMERSHAM PLC (GB) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404377-A2 | IMPROVED CHELATOR CONJUGATES | GE Healthcare Limited (GB) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003006070-A2 | IMPROVED CHELATOR CONJUGATES | AMERSHAM PLC (GB) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258619-A1 | Diaminedioxime radiometal complexes | DDO, DDT, DAO | USP2 1003/4885TSHR 507/4885ALDH1A1 2084/4885 |
| US-20060120956-A1 | Imaging agents comprising barbituric acid derivatives | CA5A, GABRA5, CA5B | USP2 3515/4885TSHR 2922/4885ALDH1A1 1222/4885 |
| US-11723991-B2 | Radiopharmaceutical compositions | TYMP, KIT, CHEK1 | USP2 1110/4885TSHR 1973/4885ALDH1A1 3697/4885 |
| US-20250186633-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | ITGB3, ITGB5, ITGAV | USP2 3227/4885TSHR 1352/4885ALDH1A1 2726/4885 |
| US-20210060189-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | TYMP, KIT, CHEK1 | USP2 1110/4885TSHR 1973/4885ALDH1A1 3697/4885 |
| US-10758635-B2 | Radiopharmaceutical compositions | TYMP, KIT, CHEK1 | USP2 1210/4885TSHR 2061/4885ALDH1A1 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.